Tags : Acute Hepatic Porphyria

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study

Shots: The P-III ENVISION study involves assessing of Givosiran vs PBO in 94 patients with AHP including patients with acute intermittent porphyria (AIP) across 18 countries in ratio 1:1              The ENVISION study resulted in meeting 1EPs & 2EPs i.e, reduction in porphyria attacks, presented at EASL on 13 Apr,2019 with its expected NDA & MAA […]Read More